The complete list of business models in the biotechnology market
Download our beautiful pitch about the biotechnology market
In our biotechnology market deck, you will find everything you need to understand the market
The biotechnology market has produced one of the most structurally diverse business model landscapes in any technology sector.
From AI-powered drug discovery platforms to gene editing toolkits and population-scale cancer screening, biotech companies monetize their science in very different ways, each with a distinct risk and return profile.
We update this list regularly as new companies emerge, business models evolve, and the industry continues to mature.
And if you want to better understand this new industry, you can download our pitch covering the biotechnology market.
A quick summary table
Here is a snapshot of the key structural patterns across biotechnology market business models.
| Metric | Value |
|---|---|
| Total business models mapped | 23 |
| Average scalability score | 7.2 / 10 |
| Average margin potential | 7.7 / 10 |
| Average defensibility score | 7.1 / 10 |
| Share of high capital intensity models | 74% (17 of 23) |
| Only model with low capital + 9/10 scalability + 9/10 margin | Life Sciences R&D SaaS |
| Models combining scalability ≥8 and defensibility ≥8 | 7 |
| Most common revenue model | Product sales (therapeutics) |
| Most common sales motion | Partnerships |
| Dominant customer segment | Enterprises (pharma, institutions) |
| Top-ranked model by composite score | In Vivo Cell Engineering |
| Lowest scalability model | Single-Asset Clinical Biotech (4/10) |
| Highest margin potential models | Life Sciences R&D SaaS, Gene Editing Platform, In Vivo Cell Engineering (9/10) |
| Models with payer diversification | Diagnostics and data monetization models |
| Capital intensity spread | 1 low, 5 medium, 17 high |
In our biotechnology market deck, we provide the data and the context to understand it
All the business models in the biotechnology market
Here is a table that maps the main business models in the biotechnology market, highlighting how they differ in scalability, margins, defensibility, capital intensity, and monetization approach.
| # | Business Model | Description | Example Companies | Scalability | Margin Potential | Defensibility | Capital Intensity | Category | Who Pays | Customer Segment | Revenue Model | Pricing Metric | Sales Motion | Key Strengths | Key Risks | Investor Perspective |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | In Vivo Cell Engineering | Reprograms cells inside patients, avoiding ex vivo manufacturing and logistics bottlenecks. | Capstan Therapeutics, Senda Biosciences | 9 | 9 | 9 | High | Biopharma | Specialty drug payers | Specialty patients | Product sales | Per treatment course | Specialist pharma | Cell-therapy economics with biologics-like scalability | Delivery and safety remain unproven | Massive upside if in vivo delivery works |
| 2 | TechBio Discovery Engine | Sells AI-enabled discovery workflows and data through pharma partnerships. | Owkin, Insitro, Isomorphic Labs, XtalPi | 9 | 8 | 7 | Medium | Data | Pharma companies | Enterprises | Licensing | Per collaboration / year | Enterprise sales | Earlier revenue with scalable software-like economics | Custom work can cap margins | Attractive if renewals prove platform value |
| 3 | Life Sciences R&D SaaS | Provides system-of-record software for biotech and pharma research workflows. | Benchling | 9 | 9 | 8 | Low | SaaS | Biotech and pharma | Enterprises | Subscription | Per seat / year | Enterprise sales | Recurring revenue with strong switching costs | Services creep slows software margins | Best software-like economics in the biotech stack |
| 4 | Early Cancer Detection | Develops population-scale screening tests for earlier cancer detection. | Grail, Delfi Diagnostics, Freenome, Thrive Earlier Detection | 9 | 8 | 8 | High | Diagnostics | Insurers and employers | Health systems | Transaction fee | Per test | Partnerships | Huge volume potential and strong data moat | Reimbursement and adoption take years | Enormous market if evidence clears reimbursement |
| 5 | RNA Platform Biopharma | Builds multiple drugs from proprietary RNA chemistry and delivery capabilities. | ADARx Pharmaceuticals, Abogen Biosciences, Laronde, ReCode Therapeutics, ReNAgade Therapeutics | 8 | 9 | 8 | High | Biopharma | Pharma and payers | Enterprises | Licensing | Per treatment course | Partnerships | One platform can spawn many assets | Delivery risk can invalidate platform | High upside if delivery generalizes across tissues |
| 6 | Gene Editing Platform | Combines proprietary editors with internal therapies and external partnerships. | Metagenomi, Tessera Therapeutics, Inscripta | 8 | 9 | 9 | High | Biopharma | Pharma and payers | Enterprises | Licensing | Per treatment course | Partnerships | Foundational IP plus multiple monetization paths | Off-target and delivery constraints | Strong moat if editor toolbox proves broad |
| 7 | TechBio Drug Builder | Uses AI and data systems to discover and own internal therapeutics. | Eikon Therapeutics, Generate Biomedicines, Xaira Therapeutics, Insilico Medicine, Valo Health | 8 | 8 | 8 | High | Biopharma | Pharma and payers | Enterprises | Licensing | Per milestone / asset | Partnerships | Better discovery economics could compound across pipeline | Can become biotech with software overhead | Compelling if technology measurably lifts hit rates |
| 8 | Omics Data Cloud | Provides compliant cloud infrastructure for storing and analyzing omics data. | DNAnexus | 8 | 7 | 7 | Medium | Data | Pharma and researchers | Institutions | Usage-based | Per dataset / year | Enterprise sales | Sticky infrastructure tied to growing omics workloads | Hyperscalers can compress differentiation | Good infrastructure bet if margins stay durable |
| 9 | Sequencing Instruments & Consumables | Sells sequencers plus recurring reagents, software, and service contracts. | Element Biosciences, Genapsys, Ultima Genomics, MGI Tech | 8 | 8 | 8 | High | Hardware | Labs and hospitals | Institutions | Product sales | Per instrument + consumables | Enterprise sales | Razor-blade model with recurring consumables | Hardware execution and incumbents matter | Installed-base growth drives outsized lifetime value |
| 10 | Biosimilars Challenger | Wins share through lower-cost biologics manufacturing and commercialization. | Samsung Bioepis, Shanghai Henlius Biotech | 8 | 6 | 6 | High | Biopharma | Payers and providers | Institutions | Product sales | Per dose / vial | Partnerships | Lower clinical risk with repeatable playbook | Price erosion can commoditize portfolio | Attractive only with cost leadership and scale |
| 11 | Focused Pipeline Biopharma | Builds a specialty franchise around several related therapeutic programs. | Alumis, MapLight Therapeutics, Neumora Therapeutics, Zenas BioPharma, Avenzo Therapeutics | 7 | 8 | 7 | High | Biopharma | Payers and partners | Specialty clinicians | Product sales | Per patient / year | Specialist sales | Portfolio breadth smooths some single-asset risk | Pipeline correlation can stay high | Better risk-adjusted biotech than one-asset stories |
| 12 | Precision Immunology Developer | Uses biomarkers and pathway insight to target defined autoimmune patient subsets. | Mirador Therapeutics, ACELYRIN, AltruBio, Odyssey Therapeutics | 7 | 9 | 7 | High | Biopharma | Payers and partners | Specialty clinicians | Product sales | Per patient / year | Specialist sales | Better efficacy positioning through patient selection | Precision may not drive broad uptake | Strong economics if biomarkers meaningfully differentiate outcomes |
| 13 | Biologics Partnering Biopharma | Discovers novel biologics and monetizes through selective partnering. | Harbour BioMed, Sotio, Genor Biopharma, Shanghai Henlius Biotech | 7 | 8 | 7 | High | Biopharma | Pharma and payers | Enterprises | Licensing | Per deal / milestone | Partnerships | Flexible monetization reduces burn and shares risk | Early partnering can cap upside | Solid model when retained economics stay meaningful |
| 14 | Oncology Diagnostics Data | Sells tumor profiling while monetizing linked clinico-genomic datasets. | Caris Life Sciences, Helix | 7 | 7 | 8 | Medium | Data | Providers, payers, pharma | Institutions | Licensing | Per test | Enterprise sales | Diversified revenue from testing and data monetization | Testing can commoditize faster than data | Best if data moat outgrows lab economics |
| 15 | Population Genomics Partnerships | Builds large linked datasets and licenses them for research collaborations. | Helix, Genuity Science, DNAnexus | 7 | 7 | 8 | Medium | Data | Pharma and health systems | Institutions | Licensing | Per collaboration / year | Enterprise sales | Longitudinal cohorts can become hard-to-replicate assets | Large datasets may lack actionability | Durable if cohorts stay exclusive and useful |
| 16 | AI Clinical Accelerator | Acquires clinical assets and improves development with software and trial systems. | Formation Bio, Apollo Therapeutics | 7 | 7 | 6 | High | Biopharma | Investors and payers | Specialty clinicians | Product sales | Per approved product | Partnerships | Better execution can raise asset value efficiently | Software cannot rescue weak assets | Interesting if trial execution is measurably superior |
| 17 | Regional Oncology Biopharma | Registers and commercializes oncology drugs within specific regional markets. | 3D Medicines, Avistone Pharmaceuticals, Biostar Technologies, Haihe Biopharma | 7 | 7 | 7 | High | Biopharma | Regional health systems | Hospitals | Product sales | Per treatment regimen | Field sales | Local execution can win without global innovation leadership | Policy and pricing pressure compress returns | Works when reimbursement access and portfolio discipline align |
| 18 | Gene Therapy Manufacturing | Pairs gene therapy pipelines with integrated vector process and manufacturing control. | Kriya Therapeutics, Castle Creek Biosciences, Forge Biologics | 7 | 8 | 8 | High | Biopharma | Payers and partners | Specialty patients | Product sales | Per one-time treatment | Specialist sales | Vertical integration can improve quality and margins | Facilities can become expensive fixed costs | Attractive only if CMC becomes true advantage |
| 19 | Oncology Asset In-Licensor | Sources external oncology assets and develops them in new territories. | ArriVent Biopharma, Everest Medicines, Haihe Biopharma, LianBio | 6 | 7 | 6 | High | Biopharma | Payers and providers | Hospitals | Product sales | Per treatment course | Partnerships | Faster path using partially de-risked external innovation | Poor deal terms destroy upside | BD quality matters more than scientific novelty |
| 20 | Infectious Disease Sequencing | Uses sequencing tests to diagnose difficult infectious diseases in acute settings. | Karius | 6 | 7 | 7 | Medium | Diagnostics | Hospitals and insurers | Institutions | Transaction fee | Per test | Enterprise sales | Clear clinical utility in hard cases | TAM smaller than oncology diagnostics | Good niche if repeat ordering stays strong |
| 21 | Cell Therapy Platform | Builds engineered cell therapies using reusable design and manufacturing systems. | ArsenalBio, AvenCell, Lyell Immunopharma, Obsidian Therapeutics, Shanghai Cell Therapy Group | 5 | 7 | 8 | High | Biopharma | Specialty drug payers | Specialty patients | Product sales | Per treatment course | Specialist sales | Premium pricing and strong technical barriers | Manufacturing complexity pressures margins | Breakthrough upside, but operations dominate outcomes |
| 22 | Biotech Holding Company | Allocates capital across multiple sourced programs and shared resources. | Apollo Therapeutics | 5 | 6 | 6 | High | Services | Pharma partners | Enterprises | Licensing | Per asset exit | Partnerships | Diversification reduces single-program blowups | Conglomerate discount can persist | Management quality drives nearly all value creation |
| 23 | Single-Asset Clinical Biotech | Concentrates value in one lead drug and its clinical milestones. | Bicara Therapeutics, CG Oncology, Upstream Bio, TauRx Pharmaceuticals, Areteia Therapeutics | 4 | 8 | 6 | High | Biopharma | Investors, then payers | Specialty clinicians | Product sales | Per patient / course | Specialist sales | Clear win can revalue company rapidly | One trial failure can collapse value | Highest beta way to play clinical de-risking |
In our biotechnology market deck, we will give you useful market maps and grids
Key insights about business models in the biotechnology market
Insights
- Life Sciences R&D SaaS is the only biotechnology model combining low capital intensity with both 9/10 scalability and 9/10 margin potential, making it the rare software-economics outlier in a sector dominated by capital-heavy, binary-risk businesses.
- 74% of biotech business models require high capital investment, confirming that the sector's central challenge is not scientific novelty but financing stamina: surviving the years between discovery and commercial launch.
- Frontier platform models in the biotechnology market, including in vivo cell engineering, gene editing, and RNA platforms, consistently score 8 to 9 on both margins and defensibility, but every single one still carries high capital intensity and unresolved delivery risk.
- Average margin potential across all 23 biotechnology models is roughly 7.7, while average defensibility sits around 7.1, meaning many biotech businesses can become lucrative if they succeed, but fewer can reliably defend those economics against competition.
- Partnership-oriented monetization appears across nearly all of the higher-scalability profiles in the biotechnology market, because licensing and milestone structures let companies capture value earlier, reduce cash burn, and create multiple inflection points before reaching full commercial scale.
- Diagnostics and data monetization models in biotech show broader payer diversity than therapeutic models, lowering dependence on a single reimbursement channel and allowing earlier, smoother revenue formation.
- The Sequencing Instruments and Consumables model stands out as the strongest hardware play in the biotechnology market because recurring reagent pull-through partially converts a one-time capital equipment sale into an annuity, improving lifetime value significantly.
In our biotechnology market deck, we identify repeatable patterns you can use if you’re building in this market
A few words about our methodology
This table maps the main business models used by startups in the biotechnology market.
To build it, we first analyzed the leading biotechnology startups and examined how each company actually generates revenue.
We then grouped similar approaches into clear business model categories. The goal was to capture meaningful differences without creating an overwhelming number of models.
Each business model is evaluated across four structural dimensions: scalability, margin potential, defensibility, and capital intensity.
Scalability measures how easily a biotech business model can grow without proportional increases in cost. Margin potential reflects the long-term gross margin typically achievable once the model reaches maturity.
Defensibility captures how sustainable the competitive advantage can be over time, considering factors like switching costs, network effects, or proprietary data.
Capital intensity indicates how much upfront investment is usually required to build and scale the model.
For scalability, margin potential, and defensibility, scores range from 0 to 10. Lower scores indicate structural limitations, while scores above 7 generally signal strong economic potential.
These scores are not precise forecasts. They reflect the typical economics we observe across biotechnology companies using that model.
This framework is part of the broader research behind our report covering the biotechnology market, where we analyze the ecosystem in much more detail.
If you want to better understand the ecosystem, you can also check our ranking of startups with the most fundraising in the biotechnology market and the list of the startups with the biggest valuations in the biotechnology market.
If you want more detail about our business model analysis or about a specific company in the biotechnology market, feel free to contact us. We will gladly explain.
In our biotechnology market deck, we identify repeatable patterns you can use if you’re building in this market
Related blog posts
- The latest news in the biotechnology market
- The latest funding news in the biotechnology market
- What has changed recently in the biotechnology market?
- How funding activity has changed in the biotechnology market
- What are the key fundraising trends in the biotechnology market?
